The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

Inclusion Criteria: * Adult patients ≥ 18 years old * Newly diagnosed or recurrent high grade glioma (HGG) or glioblastoma (GBM) (if recurrent, prior pathology report indicating HGG or GBM) * Adequate hematologic function within 14 days prior to starting evolocumab defined as follows: 1. Hemoglobin ≥ 10 g/dl (Note: the use of transfusion or other intervention to achieve Hgb ≥ 10.0 g/dl is acceptable) 2. Leukocytes ≥ 1,500/mm3 3. Absolute Neutrophil Count (ANC) ≥ 1,000/mm3 4. Platelets ≥ 100,000/mm3 * Adequate renal function within 14 days prior to starting evolocumab defined as calculated creatinine clearance (CrCL) of ≥ 30 mL/min/1.73m2 by the Cockcroft-Gault formula * Adequate hepatic function within 14 days prior to starting evolocumab defined as follows: 1. Total bilirubin ≥ 1.5 x institutional upper limit of normal (ULN) (Note: Patients with known Gilbert disease without other clinically significant liver abnormalities are not excluded.) 2. AST(SGOT) and ALT(SGPT) ≥ 1.5 × ULN * Negative serum pregnancy test (in females of childbearing potential) within 48 hours of starting evolocumab. Exclusion Criteria: * Any patient with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in evolocumab * Patients with severe hepatic impairment outside of the range defined in the inclusion criteria within 7 days of starting evolocumab. * History or evidence of central nervous system bleeding as defined by stroke or intraocular bleed (including embolic stroke) not associated with any antitumor surgery within 6 months before enrollment * Infection requiring intravenous antibiotics that was completed \< 1 week of study enrollment (day 1) with the exemption of prophylactic antibiotics for long line insertion or biopsy * Females of reproductive potential and males who are unwilling to practice an acceptable method(s) of effective birth control while on study through 1 month (2 half-lives) after receiving the last dose of study drug.